Linagliptineffects onheartfailureand relatedoutcomesin individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA. Circulation. 2019;139:351-361.
Similarly,linagliptin, another DPP-4 inhibitor, has shown a neutral cardiovascular safety profile inheartfailurepatients, supporting its use in this population. The TECOS (Trial Evaluating CardiovascularOutcomeswith Sitagliptin) trial was a landmark...
Find patient medical information forLinagliptin(Tradjenta) on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings.
As we can see from the illustration, Linagliptin Heart Failure Outcomes has many fascinating aspects to explore.
Monitor patients for manifestations ofheartfailure. Ifheartfailuredevelops, institute appropriate evaluation and management according to current standards of care and consider discontinuance oflinagliptin. Use of Fixed Combination.
Overall in Asian patients,linagliptinhad an adverse event rate similar to placebo, consistent with the overall population. Conclusions:Linagliptinshowed cardiovascular and renal safety in Asian patients with T2DM and established CVD with albuminuria and/or kidney disease.
Prevalent and incidentheartfailurein cardiovascularoutcometrials of patients with type 2 diabetes .Effect oflinagliptinvs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk. The CARMELINA randomized clinical trial .
Patients takinglinagliptinaloneāAt first, one tablet containing 5 mg oflinagliptinand 1000 mg of metformin once a day. Your doctor may gradually increase your dose until your blood sugar is controlled.
Cardiovascularoutcomestrials with sitagliptin andlinagliptinhave not shown increased major adverse cardiac events, andheartfailuresignals appear neutral overall. Weight effects are typically minimal, with most patients experiencing no clinically significant change.
